Compare AbbVie Inc (ABBV) vs Super Micro Computer Inc (SMCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Super Micro Computer Inc — how do they compare? AbbVie Inc trades at $248.45 (market cap $441.94B), while Super Micro Computer Inc trades at $35.95 (market cap $20.44B). The key difference: AbbVie Inc is far larger — about 21.6× Super Micro Computer Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| ABBV | SMCI | |
|---|---|---|
Market Cap | $441.94B | $20.44B |
Sector | Health | Technology |
52-Week High | $263.58 | $58.68 |
52-Week Low | $197.38 | $20.53 |
Enterprise Value | $506.19B | $27.96B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Super Micro Computer (SMCI) trades at $36.75, up 16.85% on strong Q4 2026 earnings, beating EPS estimates with $1.70 actual versus $0.92 expected. The stock shows bullish technical signals with moving averages supporting upward momentum, while RSI indicates potential overbought conditions. Revenue surged 93% year-over-year to $11.1 billion in Q4, though slightly below the $11.6 billion consensus, with robust FY2027 guidance of $65–72 billion revenue highlighting AI-driven demand.
Outlook remains positive due to AI infrastructure growth and earnings beats, but risks include supply chain delays and high valuation multiples. Analysts maintain a $40.40 consensus target with 36% buy ratings. Investors should weigh strong cash flow and margin expansion against competitive pressures and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →
